Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:
“Hot off the press.
- EMERALD-3 Phase III trial positive.
- Significant PFS benefit for STRIDE/Lenva + TACE.
- Trend of OS benefit.
- Trend for PFS benefit for STRIDE + TACE.”
Other articles about EMERALD-3 on OncoDaily.